It is the first day in the new job for e-Therapeutics PLC’s (LON:ETX) new chief executive, who formally took up the role Thursday.
Dr Raymond Barlow, former executive director of corporate development at Amgen, based in Switzerland, said his near-term aim was “to ensure that our resources are appropriately focused on activities that are of the greatest commercial potential”.
"e-Therapeutics is at the forefront of a new wave of science and has created a unique, computational-based drug discovery platform,” he added.
WATCH: New e-therapeutics boss "excited about the future"...
“This platform uses a range of truly cutting-edge technologies, including artificial intelligence.
"I am convinced of the value in the platform and our differentiated approach to drug discovery, which should allow us and potential partners to more efficiently discover more effective drug treatments.”
The 48-year-old will take over day to day running of the company from Iain Ross, who is currently executive chairman and fills the role vacated by Professor Malcolm Young, who stepped down last summer.
His previous responsibilities have included scientific, business and corporate roles with AstraZeneca, Crucell and Johnson & Johnson.